LUCIUS 卢修斯 艾拉司群 Elacestrant乳腺癌

艾拉司群

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Elacestrant

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:
Each film-coated tablet contains Elacestrant
dihydrochloride 100mg equivalent to

LUCIUS

乳腺癌

Elacestrant ............

Indicanion,

........................ domg.

PHARMACEUTICALS

LuciElace is an estrogen receptor antagonist
indicated for
. treatment of postmenopausal women or adult
men. with ERoositive. HER2-negative. ESR1-
men, witn Ekpo
mutated advanced or metastatie breast cancer
with disease progression following at least one

LuciElace

line of endacrina theran
Dosage and Use:

" Select patients for treatment with LuciElace
based on the presence of ESRI mutations.

Elacestrant Tablets

FDA批准

.The recommended dosage of LuciElace is on
345 mg, once daily, with food.
se interruption, reduction, or permanent
discontinuation may be required due to adverse

86mg

reactions

Storage: in a dry place and store at 20°C to25°℃
Warning:
Keep medicine out of reach of Children. Do not

Rx Only

administer LuciElace during Pregnancy and
PLEASE SEE PACKACE INSERT
Mannfactured and Marketed by

权威认证

Thongmang village. Xaythany distr
Vientiane Capital, Laos.

www.lucius.la
Warning : To be sold by retadl on prescrotion
of registered physicians only, and as directed

oy the physicion
puysician

30 Tablets

口碑质量

适应症:
艾拉司群是一种雌激素受体拮抗剂,适用于治疗绝经
后女性或成年男性,ER阳性、HER2阴性、ESR1突变
的晚期或转移性乳腺癌,且在接受至少一线内分泌治
疗后病情出现进展。
推荐剂量:
1、根据ESR1突变情况选择接受艾拉司群治疗的患者。
2、推荐剂量为每日口服一次,每次345mg:随餐服用。
3、可因不良反应而中断、减少或永久停药。